Clinical trial NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Official title: An Open-label, Multicenter, First-in-human, Phase I Dose-escalation and Expansion Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG001 in Patients With CD20-positive Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Keywords: MRG001
Antibody Drug Conjugate (ADC)
CD20
Non-Hodgkin lymphoma (NHL)
Lead sponsor: Shanghai Miracogen Inc.
Sponsor class: INDUSTRY
First posted: 2021-12-14
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a dose expansion study to assess the preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety, tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both parts.


Eligibility criteria: Inclusion Criteria:

1. Voluntarily participates in the clinical study; Fully understands and informed of this study, and provides written informed consent; Willing to follow and have the ability to complete all trial procedures.
2. Aged 18 to 80 (including 18 and 80), male or female.
3. Patients with histopathologically confirmed relapsed/refractory B-cell non-Hodgkin lymphoma.
4. Relapsed or refractory disease after standard of care treatment with anti-CD20 antibodies.
5. Patients must have at least one measurable lesion without prior local therapy according to Lugano 2014 criteria.
6. The score of ECOG for performance status is 0 or 1.
7. Patients without severe hematopoietic, liver and kidney dysfunction.
8. Expected survival time ≥ 3 months.
9. Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade 1.
10. Negative blood pregnancy test for women of childbearing potential within 7 days prior to the first dose of study drug. Patients of childbearing potential should agree to use effective contraception from signing the ICF until 3 months after the last dose of study drug.
11. The score of left ventricular ejection fraction (LVEF) is \> 50%.

Exclusion Criteria:

1. Applicable to Phase Ia: positive hepatitis B surface antigen (HBsAg), or negative HBsAg with a peripheral blood hepatitis B virus DNA copy number greater than the upper limit of normal; positive hepatitis C virus (HCV) antibody and positive HCV RNA at screening. Patients with a history of clinically significant non-viral hepatitis and cirrhosis. Applicable to Phase Ib: positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb) at screening, and peripheral blood hepatitis B virus DNA copy number greater than the upper limit of normal; positive hepatitis C virus (HCV) antibody and positive HCV RNA. Patients with a history of clinically significant non-viral hepatitis and cirrhosis (decompensated cirrhosis Child-Pugh class B, C).
2. Positive human immunodeficiency virus (HIV) antibody.
3. Any active infection requiring systemic therapy occurred within 2 weeks before enrollment.
4. Suspected or confirmed central nervous system invasion of NHL.
5. Allergic constitution or known hypersensitivity to rituximab or other anti-CD20 monoclonal antibodies and their components, or hypersensitivity to any component of MRG001.
6. Patients with uncontrolled or significant cardiovascular disease.
7. History of severe pulmonary disease.
8. Received CAR-T therapy within 3 months before enrollment.
9. Received blood transfusion within 28days before enrollment, or receiced erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and other drugs that may affect hemogram within 14 days before enrollment.
10. Current use of potent CYP3A4 inhibitors or inducers.
11. History of allogeneic stem cell transplantation or organ transplantation, or have received autologous stem cell transplantation within 3 months prior to screening, or plan to undergo stem cell transplantation.
12. Suffered from other malignancies within the last 5 years.
13. Major surgery within 6 weeks prior to enrollment or planned major surgery within the first 12 weeks after receiving study drug.
14. Patients who are receiving any approved or investigational anti-tumor treatment with antibody/fusion protein/ADC drugs, radiotherapy, chemotherapy, Chinese patent medicine or Chinese herbal medicine within 28 days before enrollment; or have participated in any approved or investigational small molecule targeted therapy within 28 days before enrollment or within 5 half-lives (whichever is shorter).
15. Received any vaccine within 28 days prior to enrollment or will receive any vaccine within 6 months after the last dose of study drug.
16. Requires treatment with glucocorticoids or other immunosuppressive agents for a certain condition within 14 days prior to enrollment.
17. An acute oncolytic reaction may occur at the discretion of the investigator.
18. Inability to complete protocol-specified study visits and study drug administration.
19. Women during pregnancy or lactation; men and women of childbearing potential who are unwilling to take prescribed appropriate contraceptive measures.
20. Other conditions inappropriate for participation in this clinical trial at the discretion of the investigator.
21. Malignant lymphoma with pathological transformation.
22. High-grade B-cell lymphoma.
23. Patient's Body Mass Index ≤ 17 kg/m2.
24. Patients with underlying medical conditions that, in the judgment of the investigator, might increase the risk of receiving study drug or might affect the safety assessment of the study drug.

Primary outcomes:
measure: Adverse Events (AEs)
timeFrame: Baseline to 90 days after the last dose of study treatment.
measure: Maximum Tolerated Dose (MTD)
timeFrame: DLT will be evaluated during the first treatment cycle (Day 1-21).
measure: Recommended Phase II Dose (RP2D)
timeFrame: Baseline to study completion (up to 15 months).
Secondary outcomes:
measure: PK parameter: Concentration-time curve
timeFrame: Baseline to 90 days after the last dose of study treatment.
measure: Immunogenicity
timeFrame: Baseline to 30 days after the last dose of study treatment
measure: Objective Response Rate (ORR)
timeFrame: Baseline to study completion (up to 15 months)
measure: Duration of Response (DoR)
timeFrame: Baseline to study completion (up to 15 months)
measure: Disease Control Rate (DCR)
timeFrame: Baseline to study completion (up to 15 months)
measure: Progression Free Survival (PFS)
timeFrame: Baseline to study completion (up to 15 months)
measure: Overall Survival (OS)
timeFrame: Baseline to study completion (up to 15 months)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital
state: Beijing
city: Beijing
country: China
facility: Peking University Cancer Hospital & Institute
state: Beijing
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Zhujiang Hospital of Southern Medical University
state: Guangdong
city: Harbin
country: China
facility: Harbin First Hospital
state: Heilongjiang
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Shenyang
country: China
facility: The First Affiliated Hospital of China Medical University
state: Liaoning
city: Shenyang
country: China
facility: Shengjing Hospital of China Medical University
state: Liaoning
city: Shanghai
country: China
facility: Shanghai East Hospital
state: Shanghai
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Jun Zhu, Doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Peking University Cancer Hospital & Institute
name: Yuqing Song, Doctor
role: PRINCIPAL_INVESTIGATOR
References: